Revvity Announces Financial Results for the Second Quarter of 2024

Rhea-AI Summary

Revvity reported Q2 2024 financial results with revenue of $692 million, down 2% reported and 1% organic. GAAP EPS was $0.45, up from $0.28 year-over-year, while adjusted EPS from continuing operations was $1.22, slightly up from $1.21. The company raised its full-year 2024 adjusted EPS guidance to $4.70-$4.80.

Segment performance varied: Life Sciences revenue decreased 7% to $314 million, with adjusted operating margin at 35.8%. Diagnostics revenue increased 1% to $378 million, with adjusted operating margin improving to 25.9%. Revvity updated its full-year revenue guidance to $2.77-$2.79 billion, assuming 2% organic growth.

Positive

• Raised full-year 2024 adjusted EPS guidance to $4.70-$4.80
• GAAP EPS increased from $0.28 to $0.45 year-over-year
• Diagnostics segment revenue grew 1% with 3% organic growth
• Diagnostics adjusted operating margin improved from 22.9% to 25.9%
• Overall adjusted operating profit margin remained stable at 28.7%

Negative

• Overall revenue decreased 2% reported and 1% organic to $692 million
• Life Sciences segment revenue declined 7% with 6% organic decrease
• Life Sciences adjusted operating margin decreased from 38.0% to 35.8%
• Adjusted EPS from continuing operations only slightly increased from $1.21 to $1.22

Insights

Financial Analyst

Revvity's Q2 2024 results present a mixed picture with some positive developments amidst challenges. The 2% reported revenue decline to $692 million and 1% organic growth indicate a challenging market environment. However, the company's ability to improve profitability is noteworthy.

Key positives include:

• GAAP EPS increase from $0.28 to $0.45 year-over-year
• Adjusted EPS slight improvement from $1.21 to $1.22
• GAAP operating profit margin expansion from 11.0% to 12.4%

The Diagnostics segment showed resilience with 1% reported and 3% organic growth, while Life Sciences faced headwinds with revenue declines. The company's ability to maintain a high adjusted operating profit margin of 28.7% despite revenue challenges is commendable.

Revvity's decision to raise its full-year 2024 adjusted EPS guidance to $4.70-$4.80 suggests management's confidence in ongoing cost management and operational efficiencies. However, the slight downward revision in revenue guidance to $2.77-$2.79 billion reflects ongoing market uncertainties.

Investors should monitor the company's ability to drive organic growth, particularly in the Life Sciences segment and its success in maintaining profitability in a challenging environment. The upcoming webcast on July 29, 2024, will be important for gaining further insights into management's strategies and outlook.

Market Research Analyst

Revvity's Q2 2024 results offer valuable insights into broader market trends in the life sciences and diagnostics sectors. The divergent performance of the two segments is particularly telling:

Life Sciences:

• 7% reported revenue decrease
• 6% organic revenue decline
• Adjusted operating profit margin compression from 38.0% to 35.8%

This suggests ongoing challenges in the life sciences tools and services market, possibly due to reduced R&D spending by pharmaceutical and biotechnology companies.

Diagnostics:

• 1% reported revenue increase
• 3% organic revenue growth
• Adjusted operating profit margin expansion from 22.9% to 25.9%

The diagnostics segment's growth indicates resilient demand for clinical diagnostics and applied genomics solutions, possibly driven by ongoing healthcare needs and personalized medicine trends.

The company's ability to raise its adjusted EPS guidance while slightly lowering revenue expectations highlights a broader industry trend of focusing on operational efficiency and cost management in the face of market uncertainties. This approach may become increasingly common among life sciences and diagnostics companies as they navigate a complex macroeconomic environment.

Investors should closely monitor these sector-specific trends and their potential impact on other companies in the life sciences and diagnostics space. The divergence between segments also underscores the importance of diversification in mitigating market-specific risks.

• Revenue of $692 million; (2)% reported growth; (1)% organic growth
• GAAP EPS of $0.45; Adjusted EPS from continuing operations of $1.22
• Raises full year 2024 adjusted EPS guidance

WALTHAM, Mass.--(BUSINESS WIRE)-- Revvity, Inc. (NYSE: RVTY), today reported financial results for the second quarter ended June 30, 2024.

The Company reported GAAP earnings per share of $0.45, as compared to $0.28 in the same period a year ago. GAAP revenue for the quarter was $692 million, as compared to $709 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $86 million, as compared to $78 million for the same period a year ago. GAAP operating profit margin from continuing operations was 12.4% as a percentage of revenue, as compared to 11.0% in the same period a year ago.

Adjusted earnings per share from continuing operations for the quarter was $1.22, as compared to $1.21 in the same period a year ago. Adjusted revenue for the quarter was $692 million, as compared to $709 million in the same period a year ago. Adjusted operating income was $199 million, as compared to $204 million for the same period a year ago. Adjusted operating profit margin was 28.7% as a percentage of adjusted revenue, as compared to 28.8% in the same period a year ago.

Adjustments for the Company's non-GAAP financial measures have been noted in the attached reconciliations.

“During the second quarter, we celebrated Revvity's one year anniversary with both pride and gratitude for what we have already accomplished as an organization and for our customers,” said Prahlad Singh, president and chief executive officer of Revvity. “Our Company's unique strengths of bringing together high levels of continuous innovation and ongoing strong execution enabled us to exceed our expectations, putting us on a good trajectory towards achieving our full year goals.”

Financial Overview by Reporting Segment

Life Sciences

• Second quarter 2024 revenue was $314 million, as compared to $336 million in the same period a year ago. Reported revenue decreased 7% and organic revenue decreased 6% as compared to the same period a year ago.
• Second quarter 2024 adjusted operating income was $112 million, as compared to $128 million in the same period a year ago. Adjusted operating profit margin was 35.8% as a percentage of adjusted revenue, as compared to 38.0% in the same period a year ago.

Diagnostics

• Second quarter 2024 revenue was $378 million, as compared to $373 million in the same period a year ago. Reported revenue increased 1% and organic revenue increased 3% as compared to the same period a year ago.
• Second quarter 2024 adjusted operating income was $98 million, as compared to $85 million in the same period a year ago. Adjusted operating profit margin was 25.9% as a percentage of adjusted revenue, as compared to 22.9% in the same period a year ago.

Full Year 2024 Guidance

For the full year 2024, the Company is updating its full year revenue guidance to $2.77-$2.79 billion to reflect recent changes in foreign currency exchange rates and assumes 2% organic revenue growth. The Company is also raising its adjusted EPS guidance to a range of $4.70-$4.80.

Guidance for the full year 2024 is provided on a non-GAAP basis and cannot be reconciled to the closest GAAP measures without unreasonable effort due to the unpredictability of the amounts and timing of events affecting the items the Company excludes from these non-GAAP measures. The timing and amounts of such events and items could be material to the Company’s results prepared in accordance with GAAP.

Webcast Information

The Company will discuss its second quarter 2024 results and its outlook for business trends during a webcast on July 29, 2024, at 8:00 a.m. Eastern Time. A live audio webcast and presentation will be available on the Investors section of the Company’s website, ir.revvity.com.

Use of Non-GAAP Financial Measures

In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings announcement also contains non-GAAP financial measures. The reasons that we use these measures, a reconciliation of these measures to the most directly comparable GAAP measures, and other information relating to these measures are included below following our GAAP financial statements.

Factors Affecting Future Performance

This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities, acquisitions and divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "estimates," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) fluctuations in the global economic and political environments; (3) our failure to introduce new products in a timely manner; (4) our ability to execute acquisitions and divestitures, license technologies, or to successfully integrate acquired businesses or licensed technologies into our existing businesses or to make them profitable; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (8) disruptions in the supply of raw materials and supplies; (9) our ability to retain key personnel; (10) significant disruption in our information technology systems, or cybercrime; (11) our ability to realize the full value of our intangible assets; (12) our failure to adequately protect our intellectual property; (13) the loss of any of our licenses or licensed rights; (14) the manufacture and sale of products exposing us to product liability claims; (15) our failure to maintain compliance with applicable government regulations; (16) our failure to comply with data privacy and information security laws and regulations; (17) regulatory changes; (18) our failure to comply with healthcare industry regulations; (19) economic, political and other risks associated with foreign operations; (20) our ability to obtain future financing; (21) restrictions in our credit agreements; (22) significant fluctuations in our stock price; (23) reduction or elimination of dividends on our common stock; and (24) other factors which we describe under the caption "Risk Factors" in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

About Revvity

At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2023 revenue of more than $2.7 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries.

Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.

Revvity, Inc. and Subsidiaries
CONDENSED CONSOLIDATED INCOME STATEMENTS
		Three Months Ended								Six Months Ended
(In thousands, except per share data)		June 30, 2024				July 2, 2023				June 30, 2024				July 2, 2023
Revenue		$	691,685			$	709,066			$	1,341,605			$	1,383,931
Cost of revenue			306,179				306,735				601,052				600,234
Selling, general and administrative expenses			251,650				267,022				512,221				515,579
Research and development expenses			48,132				57,253				98,492				113,943
Operating income from continuing operations			85,724				78,056				129,840				154,175
Interest income			(20,512	)			(25,046	)			(40,598	)			(30,318	)
Interest expense			24,717				26,007				49,114				48,745
Change in fair value of financial securities			(7,777	)			2,023				(6,971	)			(745	)
Other expense, net			2,634				3,518				7,084				35,499
Income from continuing operations, before income taxes			86,662				71,554				121,211				100,994
Provision for income taxes			14,056				12,932				19,909				17,527
Income from continuing operations			72,606				58,622				101,302				83,467
(Loss) income from discontinued operations			(17,246	)			(23,063	)			(19,929	)			521,567
Net income		$	55,360			$	35,559			$	81,373			$	605,034
Diluted earnings per share:
Income from continuing operations		$	0.59			$	0.47			$	0.82			$	0.66
(Loss) income from discontinued operations			(0.14	)			(0.18	)			(0.16	)			4.14
Net income		$	0.45			$	0.28			$	0.66			$	4.80
Weighted average diluted shares of common stock outstanding			123,477				125,398				123,494				125,918
ABOVE PREPARED IN ACCORDANCE WITH GAAP
Additional supplemental information (1):
(per share, continuing operations)
GAAP EPS from continuing operations		$	0.59			$	0.47			$	0.82			$	0.66
Amortization of intangible assets			0.73				0.74				1.47				1.47
Debt extinguishment costs			-				-				-				(0.03	)
Purchase accounting adjustments			0.01				0.02				0.06				0.02
Acquisition and divestiture-related costs			0.04				0.20				0.11				0.55
Change in fair value of financial securities			(0.06	)			0.02				(0.06	)			(0.01	)
Significant litigation matters and settlements			0.05				-				0.05				-
Significant environmental matters			-				-				-				0.01
Restructuring and other, net			0.08				0.02				0.18				0.04
Tax on above items			(0.21	)			(0.25	)			(0.44	)			(0.48	)
Significant tax items			-				-				-				(0.01	)
Adjusted EPS from continuing operations		$	1.22			$	1.21			$	2.19			$	2.22
(1) amounts may not sum due to rounding

Revvity, Inc. and Subsidiaries
REVENUE AND OPERATING INCOME (LOSS)
		Three Months Ended								Six Months Ended
(In thousands, except percentages)		June 30, 2024				July 2, 2023				June 30, 2024				July 2, 2023
Adjusted revenue and operating income
Reported revenue		$	691,685			$	709,066			$	1,341,605			$	1,383,931
Revenue purchase accounting adjustments			207				206				416				412
Adjusted revenue			691,892				709,272				1,342,021				1,384,343
Reported operating income from continuing operations			85,724				78,056				129,840				154,175
OP%			12.4	%			11.0	%			9.7	%			11.1	%
Amortization of intangible assets			90,620				92,758				181,858				184,569
Purchase accounting adjustments			623				2,891				7,245				1,977
Acquisition and divestiture-related costs			5,779				28,579				17,241				46,530
Significant litigation matters and settlements			6,276				—				6,276				—
Significant environmental matters			—				—				—				1,132
Restructuring and other, net			9,845				2,009				22,201				5,104
Adjusted operating income		$	198,867			$	204,293			$	364,661			$	393,487
OP%			28.7	%			28.8	%			27.2	%			28.4	%
Segment revenue and segment operating income
Life Sciences		$	313,847			$	336,353			$	616,884			$	664,794
Diagnostics			378,045				372,919				725,137				719,549
Revenue purchase accounting adjustments			(207	)			(206	)			(416	)			(412	)
Reported revenue			691,685				709,066				1,341,605				1,383,931
Life Sciences		$	112,401			$	127,759			$	214,126			$	257,218
			35.8	%			38.0	%			34.7	%			38.7	%
Diagnostics			97,915				85,241				173,345				159,673
			25.9	%			22.9	%			23.9	%			22.2	%
Corporate			(11,449	)			(8,707	)			(22,810	)			(23,404	)
Subtotal reportable segments operating income			198,867				204,293				364,661				393,487
Amortization of intangible assets			(90,620	)			(92,758	)			(181,858	)			(184,569	)
Purchase accounting adjustments			(623	)			(2,891	)			(7,245	)			(1,977	)
Acquisition and divestiture-related costs			(5,779	)			(28,579	)			(17,241	)			(46,530	)
Significant litigation matters and settlements			(6,276	)			—				(6,276	)			—
Significant environmental matters			—				—				—				(1,132	)
Restructuring and other, net			(9,845	)			(2,009	)			(22,201	)			(5,104	)
Reported operating income from continuing operations		$	85,724			$	78,056			$	129,840			$	154,175
REPORTED REVENUE AND REPORTED OPERATING INCOME (LOSS) PREPARED IN ACCORDANCE WITH GAAP

Revvity, Inc. and Subsidiaries
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)		June 30, 2024			December 31, 2023
Current assets:
Cash and cash equivalents		$	1,248,120		$	913,163
Marketable securities			706,070			689,916
Accounts receivable, net			597,436			632,811
Inventories, net			401,432			428,062
Other current assets			205,631			337,139
Total current assets			3,158,689			3,001,091
Property, plant and equipment, net			503,119			509,654
Operating lease right-of-use assets, net			143,789			155,083
Intangible assets, net			2,825,487			3,022,321
Goodwill			6,496,971			6,533,550
Other assets, net			296,794			342,966
Total assets		$	13,424,849		$	13,564,665
Current liabilities:
Current portion of long-term debt		$	711,414		$	721,872
Accounts payable			174,871			204,121
Accrued expenses and other current liabilities			503,728			524,470
Total current liabilities			1,390,013			1,450,463
Long-term debt			3,162,600			3,177,770
Long-term liabilities			878,788			930,946
Operating lease liabilities			123,134			132,747
Total liabilities			5,554,535			5,691,926
Total stockholders' equity			7,870,314			7,872,739
Total liabilities and stockholders' equity		$	13,424,849		$	13,564,665
PREPARED IN ACCORDANCE WITH GAAP

Revvity, Inc. and Subsidiaries
CONSOLIDATED STATEMENTS OF CASH FLOWS
		Three Months Ended								Six Months Ended
		June 30, 2024				July 2, 2023				June 30, 2024				July 2, 2023
		(In thousands)								(In thousands)
Operating activities:
Net income		$	55,360			$	35,559			$	81,373			$	605,034
Loss (income) from discontinued operations, net of income taxes			17,246				23,063				19,929				(521,567	)
Income from continuing operations			72,606				58,622				101,302				83,467
Adjustments to reconcile income from continuing operations to net cash provided by (used in) continuing operations:
Stock-based compensation			10,526				13,633				22,218				23,526
Restructuring and other, net			9,845				2,009				22,201				5,104
Depreciation and amortization			107,344				108,930				215,146				217,938
Change in fair value of contingent consideration			176				2,445				6,349				1,085
Amortization of deferred debt financing costs and accretion of discounts			1,773				2,026				3,509				3,818
Change in fair value of financial securities			(7,777	)			2,023				(6,971	)			(745	)
Debt extinguishment gain			—				—				—				(3,345	)
Unrealized foreign exchange (gain) loss			(480	)			(2,416	)			(857	)			23,679
Changes in assets and liabilities which provided (used) cash, excluding effects from companies acquired:
Accounts receivable, net			(8,995	)			(44,640	)			28,194				(10,216	)
Inventories			10,042				(8,255	)			17,251				(26,775	)
Accounts payable			(4,747	)			(44,330	)			(22,974	)			(49,225	)
Accrued expenses and other			(7,985	)			(137,195	)			(52,894	)			(240,285	)
Net cash provided by (used in) operating activities of continuing operations			182,328				(47,148	)			332,474				28,026
Net cash used in operating activities of discontinued operations			(23,707	)			(88,171	)			(26,290	)			(99,882	)
Net cash provided by (used in) operating activities			158,621				(135,319	)			306,184				(71,856	)
Investing activities:
Capital expenditures			(22,031	)			(13,949	)			(39,875	)			(34,895	)
Purchases of investments and notes receivables			(4,000	)			(5,000	)			(4,337	)			(5,000	)
Purchases of U.S. Treasury Securities			—				(637,765	)			—				(831,219	)
Proceeds from U.S. Treasury Securities			—				100,000				—				100,000
Cash paid for acquisitions, net of cash acquired			—				—				—				(686	)
Net cash used in investing activities of continuing operations			(26,031	)			(556,714	)			(44,212	)			(771,800	)
Net cash provided by (used in) investing activities of discontinued operations			147,522				(14,327	)			147,522				2,065,261
Net cash provided by (used in) investing activities			121,491				(571,041	)			103,310				1,293,461
Financing Activities:
Payments of debt financing costs			—				(15	)			—				(15	)
Payments of senior unsecured notes			—				(1,232	)			—				(50,835	)
Net (payments) proceeds on other credit facilities			(389	)			(636	)			(11,200	)			7,231
Payments for acquisition-related contingent consideration			—				(8,642	)			(8,749	)			(10,117	)
Proceeds from issuance of common stock under stock plans			2,089				2,692				6,032				3,215
Purchases of common stock			(19,553	)			(211,643	)			(30,309	)			(273,299	)
Dividends paid			(8,642	)			(8,797	)			(17,282	)			(17,638	)
Net cash used in financing activities			(26,495	)			(228,273	)			(61,508	)			(341,458	)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash			(3,654	)			(602	)			(12,931	)			(17,571	)
Net increase (decrease) in cash, cash equivalents, and restricted cash			249,963				(935,235	)			335,055				862,576
Cash, cash equivalents, and restricted cash at beginning of period			999,465				2,268,557				914,373				470,746
Cash, cash equivalents, and restricted cash at end of period		$	1,249,428			$	1,333,322			$	1,249,428			$	1,333,322
Supplemental disclosure of cash flow information:
Reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total shown in the consolidated statements of cash flows:
Cash and cash equivalents		$	1,248,120			$	1,331,903			$	1,248,120			$	1,331,903
Restricted cash included in other current assets			1,308				1,062				1,308				1,062
Restricted cash included in other assets			—				357				—				357
Total cash, cash equivalents and restricted cash		$	1,249,428			$	1,333,322			$	1,249,428			$	1,333,322
PREPARED IN ACCORDANCE WITH GAAP

Revvity, Inc. and Subsidiaries
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (1)
		Continuing Operations
		Three Months Ended
		June 30, 2024
Organic revenue growth:
Reported revenue growth from continuing operations		-2%
Less: effect of foreign exchange rates		-1%
Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses		0%
Organic revenue growth from continuing operations		-1%
		Life Sciences
		Three Months Ended
		June 30, 2024
Organic revenue growth:
Reported revenue growth from continuing operations		-7%
Less: effect of foreign exchange rates		-1%
Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses		0%
Organic revenue growth from continuing operations		-6%
		Diagnostics
		Three Months Ended
		June 30, 2024
Organic revenue growth:
Reported revenue growth from continuing operations		1%
Less: effect of foreign exchange rates		-1%
Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses		0%
Organic revenue growth from continuing operations		3%
(1) amounts may not sum due to rounding

Revvity, Inc. and Subsidiaries
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (1)
		Continuing Operations
		Six Months Ended
		June 30, 2024
Organic revenue growth:
Reported revenue growth from continuing operations		-3%
Less: effect of foreign exchange rates		-1%
Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses		0%
Organic revenue growth from continuing operations		-2%
		Life Sciences
		Six Months Ended
		June 30, 2024
Organic revenue growth:
Reported revenue growth from continuing operations		-7%
Less: effect of foreign exchange rates		0%
Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses		0%
Organic revenue growth from continuing operations		-7%
		Diagnostics
		Six Months Ended
		June 30, 2024
Organic revenue growth:
Reported revenue growth from continuing operations		1%
Less: effect of foreign exchange rates		-1%
Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses		0%
Organic revenue growth from continuing operations		2%
		Continuing Operations
		Twelve Months Ended
		December 29, 2024
		Projected
Organic revenue growth:
Reported revenue growth from continuing operations		1%
Less: effect of foreign exchange rates		-1%
Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses		0%
Organic revenue growth from continuing operations		2%
(1) amounts may not sum due to rounding

Explanation of Non-GAAP Financial Measures

We report our financial results in accordance with GAAP. However, management believes that, in order to more fully understand our short-term and long-term financial and operational trends, investors may wish to consider the impact of certain non-cash, non-recurring or other items, which result from facts and circumstances that vary in frequency and impact on continuing operations. Accordingly, we present non-GAAP financial measures as a supplement to the financial measures we present in accordance with GAAP. These non-GAAP financial measures provide management with additional means to understand and evaluate the operating results and trends in our ongoing business by adjusting for certain non-cash expenses and other items that management believes might otherwise make comparisons of our ongoing business with prior periods more difficult, obscure trends in ongoing operations, or reduce management's ability to make useful forecasts. Management believes these non-GAAP financial measures provide additional means of evaluating period-over-period operating performance. In addition, management understands that some investors and financial analysts find this information helpful in analyzing our financial and operational performance and comparing this performance to our peers and competitors.

We use the term “adjusted revenue” to refer to GAAP revenue, including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules. We use the related term “adjusted revenue growth” to refer to the measure of comparing current period adjusted revenue with the corresponding period of the prior year.

We use the term “organic revenue” to refer to GAAP revenue, excluding the effect of foreign currency changes and revenue from recent acquisitions and divestitures and including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules. We use the related term “organic revenue growth” to refer to the measure of comparing current period organic revenue with the corresponding period of the prior year.

We use the term “adjusted gross margin” to refer to GAAP gross margin, excluding amortization of intangible assets and inventory fair value adjustments related to business acquisitions, asset impairments, and including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to business combination accounting rules. We use the related term “adjusted gross margin percentage” to refer to adjusted gross margin as a percentage of adjusted revenue.

We use the term “adjusted SG&A expense” to refer to GAAP SG&A expense, excluding amortization of intangible assets, purchase accounting adjustments, acquisition and divestiture-related expenses, significant litigation matters and settlements, asset impairments, significant environmental charges, and restructuring and other charges. We use the related term “adjusted SG&A percentage” to refer to adjusted SG&A expense as a percentage of adjusted revenue.

We use the term “adjusted R&D expense” to refer to GAAP R&D expense, excluding amortization of intangible assets and purchase accounting adjustments. We use the related term “adjusted R&D percentage” to refer to adjusted R&D expense as a percentage of adjusted revenue.

We use the term “adjusted net interest and other expense” to refer to GAAP net interest and other expense, excluding adjustments for mark-to-market accounting on post-retirement benefits, changes in foreign exchange and interest associated with acquisitions and divestitures, changes in the value of financial securities and debt extinguishment costs.

We use the term “adjusted operating income” to refer to GAAP operating income, including revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules, and excluding amortization of intangible assets, other purchase accounting adjustments, acquisition and divestiture-related expenses, significant litigation matters and settlements, significant environmental charges, asset impairments, and restructuring and other charges. We use the related terms “adjusted operating profit percentage,” “adjusted operating profit margin,” or “adjusted operating margin” to refer to adjusted operating income as a percentage of adjusted revenue.

We use the term “free cash flow” to refer to net cash provided by (used in) operating activities of continuing operations, less payments for additions to property, plant and equipment from continuing operations (“capital expenditures”) plus the proceeds from sales of plant, property and equipment from continuing operations (“capital disposals”).

We use the term “adjusted net income,” to refer to GAAP income from continuing operations, including revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules, and excluding amortization of intangible assets, debt extinguishment costs, other purchase accounting adjustments, acquisition and divestiture-related expenses, significant litigation matters and settlements, significant environmental charges, changes in the value of financial securities, disposition of businesses and assets, net, changes in foreign exchange and interest associated with acquisitions and divestitures, asset impairments and restructuring and other charges. We also exclude adjustments for mark-to-market accounting on post-retirement benefits, therefore only our projected costs have been used to calculate this non-GAAP measure. We also adjust for any tax impact related to the above items and exclude the impact of significant tax events.

We use the term “adjusted earnings per share from continuing operations” or “adjusted earnings per share,” or “adjusted EPS," to refer to GAAP earnings per share from continuing operations, including revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules, and excluding amortization of intangible assets, debt extinguishment costs, other purchase accounting adjustments, acquisition and divestiture-related expenses, significant litigation matters and settlements, significant environmental charges, changes in the value of financial securities, disposition of businesses and assets, net, changes in foreign exchange and interest associated with acquisitions and divestitures, asset impairments and restructuring and other charges. We also exclude adjustments for mark-to-market accounting on post-retirement benefits, therefore only our projected costs have been used to calculate this non-GAAP measure. We also adjust for any tax impact related to the above items and exclude the impact of significant tax events.

Management includes or excludes the effect of each of the items identified below in the applicable non-GAAP financial measure referenced above for the reasons set forth below with respect to that item:

• Amortization of intangible assets—purchased intangible assets are amortized over their estimated useful lives and generally cannot be changed or influenced by management after the acquisition. Accordingly, this item is not considered by management in making operating decisions. Management does not believe such charges accurately reflect the performance of our ongoing operations for the period in which such charges are incurred.
• Debt extinguishment costs—we incur costs and income related to the extinguishment of debt; including make-whole payments to debt holders, accelerated amortization of debt fees and discounts, and expense or income from hedges to lock in make-whole payments. We exclude the impact of these items from our non-GAAP measures because we believe they do not reflect the performance of our ongoing operations.
• Revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules—accounting rules require us to account for the fair value of revenue from contracts assumed in connection with our acquisitions. As a result, our GAAP results reflect the fair value of those revenues, which is not the same as the revenue that otherwise would have been recorded by the acquired entity. We include such revenue in our non-GAAP measures because we believe the fair value of such revenue does not accurately reflect the performance of our ongoing operations for the period in which such revenue is recorded.
• Other purchase accounting adjustments—accounting rules require us to adjust various balance sheet accounts, including inventory, fixed assets and deferred rent balances to fair value at the time of the acquisition. As a result, the expenses for these items in our GAAP results are not the same as what would have been recorded by the acquired entity. Accounting rules also require us to estimate the fair value of contingent consideration at the time of the acquisition, and any subsequent changes to the estimate or payment of the contingent consideration and purchase accounting adjustments are charged to expense or income. We exclude the impact of any changes to contingent consideration from our non-GAAP measures because we believe these expenses or benefits do not accurately reflect the performance of our ongoing operations for the period in which such expenses or benefits are recorded.
• Acquisition and divestiture-related expenses—we incur legal, due diligence, stay bonuses, incentive awards, stock-based compensation, interest, foreign exchange gains and losses, integration expenses, rebranding expenses, and other costs related to acquisitions and divestitures. We exclude these expenses from our non-GAAP measures because we believe they do not reflect the performance of our ongoing operations.
• Asset impairments—we incur expense related to asset impairments. Management does not believe such charges accurately reflect the performance of our ongoing operations for the periods in which such charges were incurred.
• Restructuring and other charges—restructuring and other charges consist of employee severance, other exit costs as well as the cost of terminating certain lease agreements or contracts as well as costs associated with relocating facilities. Management does not believe such costs accurately reflect the performance of our ongoing operations for the period in which such costs are reported.
• Adjustments for mark-to-market accounting on post-retirement benefits—we exclude adjustments for mark-to-market accounting on post-retirement benefits, and therefore only our projected costs are used to calculate our non-GAAP measures. We exclude these adjustments because they do not represent what we believe our investors consider to be costs of producing our products, investments in technology and production, and costs to support our internal operating structure.
• Significant litigation matters and settlements—we incur expenses related to significant litigation matters, including the costs to settle or resolve various claims and legal proceedings. Management does not believe such charges accurately reflect the performance of our ongoing operations for the periods in which such charges were incurred.
• Significant environmental charges—we incur expenses related to significant environmental charges. Management does not believe such charges accurately reflect the performance of our ongoing operations for the periods in which such charges were incurred.
• Disposition of businesses and assets, net—we exclude the impact of gains or losses from the disposition of businesses and assets from our adjusted earnings per share. Management does not believe such gains or losses accurately reflect the performance of our ongoing operations for the period in which such gains or losses are reported.
• Impact of foreign currency changes on the current period—we exclude the impact of foreign currency associated with acquisitions and divestitures from these measures by using the prior period’s foreign currency exchange rates for the current period because foreign currency exchange rates are subject to volatility and can obscure underlying trends.
• Impact of significant tax events—we exclude the impact of significant tax events. Management does not believe the impact of significant tax events accurately reflects the performance of our ongoing operations for the periods in which the impact of such events was recorded.
• Changes in value of financial securities—we exclude the impact of changes in the value of financial securities. Management does not believe such gains or losses accurately reflect the performance of our ongoing operations for the period in which such gains or losses are reported.

The tax effect for discontinued operations is calculated based on the authoritative guidance in the Financial Accounting Standards Board’s Accounting Standards Codification 740, Income Taxes. The tax effect for amortization of intangible assets, inventory fair value adjustments related to business acquisitions, changes to the fair values assigned to contingent consideration, debt extinguishment costs, other costs related to business acquisitions and divestitures, significant litigation matters and settlements, significant environmental charges, changes in the fair value of financial securities, adjustments for mark-to-market accounting on post-retirement benefits, disposition of businesses and assets, net, restructuring and other charges, and the revenue from contracts acquired with various acquisitions is calculated based on operational results and applicable jurisdictional law, which contemplates tax rates currently in effect to determine our tax provision. The tax effect for the impact from foreign currency exchange rates on the current period is calculated based on the average rate currently in effect to determine our tax provision.

The non-GAAP financial measures described above are not meant to be considered superior to, or a substitute for, our financial statements prepared in accordance with GAAP. There are material limitations associated with non-GAAP financial measures because they exclude charges that have an effect on our reported results and, therefore, should not be relied upon as the sole financial measures by which to evaluate our financial results. Management compensates and believes that investors should compensate for these limitations by viewing the non-GAAP financial measures in conjunction with the GAAP financial measures. In addition, the non-GAAP financial measures included in this earnings announcement may be different from, and therefore may not be comparable to, similar measures used by other companies.

Each of the non-GAAP financial measures listed above is also used by our management to evaluate our operating performance, communicate our financial results to our Board of Directors, benchmark our results against our historical performance and the performance of our peers, evaluate investment opportunities including acquisitions and discontinued operations, and determine the bonus payments for senior management and employees.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240729804570/en/

Investor Relations:

Steve Willoughby

steve.willoughby@revvity.com

Media:

Fara Goldberg (781) 663-5699

fara.goldberg@revvity.com

Source: Revvity

FAQ

What was Revvity's (RVTY) revenue for Q2 2024?

Revvity's revenue for Q2 2024 was $692 million, representing a 2% decrease in reported growth and a 1% decrease in organic growth compared to the same period last year.

How did Revvity's (RVTY) EPS change in Q2 2024?

Revvity's GAAP EPS increased from $0.28 to $0.45 year-over-year, while adjusted EPS from continuing operations slightly increased from $1.21 to $1.22.

What is Revvity's (RVTY) updated full-year 2024 guidance?

Revvity updated its full-year 2024 revenue guidance to $2.77-$2.79 billion, assuming 2% organic growth. The company also raised its adjusted EPS guidance to a range of $4.70-$4.80.

How did Revvity's (RVTY) Diagnostics segment perform in Q2 2024?

Revvity's Diagnostics segment revenue increased 1% to $378 million, with 3% organic growth. The segment's adjusted operating margin improved from 22.9% to 25.9% year-over-year.